Amendments to the Claims:

Claim 1. (original) A triazole compound of a formula (I) or a pharmacologically acceptable salt thereof:



(I)

wherein

X represents a group of a formula (II),



(II)

wherein

Ar represents a C_6-C_{10} aryl group which is unsubstituted or substituted with 1 to 3 of the same or different groups selected from the group consisting of a halogen atom and a halogenated C_1-C_6 alkyl group, and

R^1 represents an organic residue group,

provided that a compound of a formula X-OH has antifungal activity,

L represents a group of a formula $-L^a-L^b-$

wherein

L^a represents a single bond, an oxygen atom, a C_6-C_{10} aryl group which is unsubstituted or substituted with 1 to 3 same or different groups selected from the group consisting of a Substituent group α, a heterocyclic group which is unsubstituted

or substituted with 1 to 3 of the same or different groups selected from the group consisting of the Substituent group α, and a C_3-C_7 cycloalkyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the Substituent group α, and

L^b represents a C_1-C_5 alkylene group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the Substituent group α, and

R represents a hydrogen atom, a C_1-C_6 alkanoyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups selected from the group consisting of a Substituent group β, a group of formula $-C(O)-NR^2R^3$, wherein R^2 and R^3 are the same or different and independently represent a hydrogen atom or a C_1-C_6 alkyl group, or R^2 and R^3, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclic group containing one or more nitrogen atoms or a $-P(=O)(OH)_2$ group,

Substituent group α is selected from the group consisting of

a C_1-C_6 alkyl group, a C_1-C_6 alkoxy group, a halogen atom, a cyano group, a hydroxy group, an amino group, a C_1-C_6 alkylamino group, a di C_1-C_6 alkylamino group, an amino C_1-C_6 alkyl group, a C_1-C_6 alkylamino-C_1-C_6 alkyl group, a di C_1-C_6 alkylamino-C_1-C_6 alkyl group, a carboxy group, a $-O-P(=O)(OH)_2$ group, and a C_1-C_6 alkyl group substituted with one $-O-P(=O)(OH)_2$ group, and

Substituent group β is selected from the group consisting of

a hydroxy group; a $-Q-NR^{2'}R^{3'}$ group, wherein Q represents a

single bond or a carbonyl group, and $R^{2'}$ and $R^{3'}$ are the same or different and independently represent a hydrogen atom or a C_1-C_6 alkyl group, or $R^{2'}$ and $R^{3'}$, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclic group containing one or more nitrogen atoms, said heterocyclic group containing one or more nitrogen atoms is unsubstituted or substituted with 1 or 2 of the same or different C_1-C_6 alkyl groups; a carboxy group; an $-O-P(=O)(OH)_2$ group and a $-SO_3H$ group.

Claim 2. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein L^a represents a C_6-C_{10} aryl group which is unsubstituted or substituted with 1 to 3 of the same or different groups selected from the group consisting of the Substituent group α, a heterocyclic group which is unsubstituted or substituted with 1 to 3 of the same or different groups selected from the group consisting of the Substituent group α, or a C_3-C_7 cycloalkyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the Substituent group α.

Claim 3. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 2, wherein the carbon atom in the group of $-L^a-$ to which the group of formula X-O-C(=O)- is bonded and the carbon atom in the group of $-L^a-$ to which the group of formula $-L^b-O-R$ is bonded are adjacent to each other.

Claim 4. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein L^b represents an unsubstituted methylene group or a methylene group which is substituted with 1 or 2 of the same or different groups from the Substituent group α.

Claim 5. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein L represents an unsubstituted -(o-phenylene)-CH_2- group or an -(o-phenylene)-CH_2- group which is substituted with one group from the Substituent group α.

Claim 6. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 5, wherein L represents an -(o-phenylene)-CH_2- group which is substituted with one group from the Substituent group α.

Claim 7. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein R represents a hydrogen atom.

Claim 8. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein R represents a C_1-C_6 alkanoyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the Substituent group β.

Claim 9. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein R represents a $-P(=O)(OH)_2$ group.

Claim 10. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein the Substituent group α represents a Substituent group α1 which is selected from the group consisting of a methyl group, a methoxy group, a halogen atom, a cyano group and a $-CH_2-O-P(=O)(OH)_2$ group.

Claim 11. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein the Substituent group β represents a Substituent group β1 which is selected from the group consisting of an amino group, a C_1-C_6 alkylamino group and a di C_1-C_6 alkylamino group.

Claim 12. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 11, wherein the Substituent group β represents a di C_1-C_6 alkylamino group.

Claim 13. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 12, wherein the Substituent group β represents an N,N-dimethylamino group.

Claim 14. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein the Substituent group β represents a carboxy group.

Claim 15. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein the Substituent group β represents a 4- to 7-membered heterocyclic group containing one or more nitrogen atoms, said heterocyclic group containing one or more nitrogen atoms is unsubstituted or substituted with 1 or 2 C_1-C_6 alkyl groups which are the same or different.

Claim 16. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 15, wherein the Substituent group β represents a 4- to 7-membered heterocyclic group containing one or more nitrogen atoms, said heterocyclic group containing one or more nitrogen atoms is substituted with 1 or 2 C_1-C_6 alkyl groups which are the same or different.

Claim 17. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 16, wherein Substituent group β represents a 4-methyl-1-piperazinyl group.

Claim 18. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein the Substituent group β represents a group of formula

-C(O)-W, wherein W represents a 4- to 7-membered heterocyclic group containing one or more nitrogen atoms, said heterocyclic group containing one or more nitrogen atoms is unsubstituted or substituted with 1 or 2 C_1-C_6 alkyl groups which are the same or different.

Claim 19. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 18, wherein Substituent group β represents a group of formula -C(O)-W^1, wherein W^1 represents a 4- to 7-membered heterocyclic group containing one or more nitrogen atoms, said heterocyclic group containing one or more nitrogen atoms is substituted with 1 or 2 of the same or different C_1-C_6 alkyl groups.

Claim 20. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 19, wherein the Substituent group β represents a (4-methyl-1-piperazinyl)carbonyl group.

Claim 21. (currently amended) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (III),



(III)

wherein Ar^1 represents a phenyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups selected from the group consisting of a halogen atom and a trifluoromethyl group,

Ar^2 represents a phenyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups from the Substituent group γ; a monocyclic heteroaryl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of the Substituent group γ; a naphthyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of the Substituent group γ; and a fused bicyclic heteroaryl group which is unsubstituted or substituted with 1 to 5 of the same or different groups from the Substituent group γ,

E represents a methylene group or a group of formula $-S(O)_{n1}-$ wherein, n1 is an integer from 0 to 2,

A^1 represents a C_4-C_7 cycloalkyl group or a heterocyclyl group,

R^4 and R^5 independently represent a hydrogen atom or a C_1-C_6 alkyl group,

G represents a group of a formula (Ga)

$$—(CO)_p—(R^6C=CR^7)_q—(C\equiv C)_r—(R^8C=CR^9)_s—\qquad (Ga)$$

wherein R^6, R^7, R^8 and R^9 independently represent a hydrogen atom or a C_1-C_6 alkyl group which is unsubstituted or substituted with 1 to 5 of the same or different halogen atoms,

p is an integer 0 or 1,

q is an integer from 0 to 3, and

r and s independently are an integer from 0 to 2[[)]],

or G represents a group of a formula (Gb)[[)]]

$$-\Phi\text{-}CO\text{-}NR^{\Psi}\text{—}T\text{—} \quad (Gb)$$

wherein ϕ represents a phenylene group which is unsubstituted or substituted with 1 or 2 of the same or different groups selected from the group consisting of a fluorine atom and a chlorine atom, or a naphthylene group which is unsubstituted or substituted with 1 or 2 of the same or different groups selected from the group consisting of a fluorine atom and a chlorine atom,

R^{Ψ} represents a hydrogen atom or a C_1-C_6 alkyl group, and

T represents a single bond or a straight or branched chain C_1-C_8 alkylene group, and

the Substituent group γ is selected from the group consisting of a halogen atom, a hydroxy group, a mercapto group, a nitro group, an amino group, a cyano group, a carboxy group, a C_1-C_6 alkyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of a Substituent group ζ, a C_1-C_6 alkoxy group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of the Substituent group ζ, a C_1-C_6 alkanoyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of the Substituent group ζ, a C_2-C_6 alkanoyloxy group which may optionally be substituted with 1 to 5 same or different

groups selected from the group consisting of the Substituent group ζ, a C_2-C_7 alkoxycarbonyl group, a C_2-C_5 alkanoylamino group, a group of formula $-C(O)-NR^{2a}R^{3a}$, wherein, R^{2a} and R^{3a} independently represent a hydrogen atom or a C_1-C_6 alkyl group, or R^{2a} and R^{3a}, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclic group containing one or more nitrogen atoms, a group of formula $-S(O)_{\mu 1}-R^{\xi 1}$, wherein μ1 is an integer from 0 to 2 and $R^{\xi 1}$ represents a C_1-C_6 alkyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of a Substituent group η, a group of formula $-S(O)_{\mu 2}-O-R^{\xi 2}$, wherein, μ2 is an integer from 0 to 2 and $R^{\xi 2}$ represents a C_1-C_6 alkyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of the Substituent group η, a group of formula $-O-S(O)_{\mu 3}-R^{\xi 3}$, wherein μ3 is an integer from 0 to 2 and $R^{\xi 3}$ represents a C_1-C_6 alkyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of Substituent group η, an imidazolyl group which is unsubstituted or substituted with 1 or 2 of the same or different groups selected from the group consisting of the Substituent group δ, a pyrazolyl group which is unsubstituted or substituted with 1 or 2 of the same or different groups selected from the group consisting of the Substituent group δ, a triazolyl group which is unsubstituted or substituted with 1 or 2 of the same or different groups selected from the group consisting of the Substituent group δ, a tetrazolyl group which is unsubstituted or

substituted with 1 or 2 of the same or different groups selected from the group consisting of the Substituent group δ, a C_2-C_6 alkenyl group, a C_2-C_6 alkynyl group, a C_3-C_6 cycloalkyl group, and a C_1-C_6 alkyl group which is substituted with a C_3-C_6 cycloalkyl group;

Substituent group δ is selected from the group consisting of a C_1-C_4 alkyl group, a C_1-C_4 alkyl group which is substituted with 1 to 5 of the same or different halogen atoms, and a halogen atom;

Substituent group ζ is selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, and a C_1-C_6 alkoxy group;

Substituent group η is selected from the group consisting of a halogen atom and a hydroxy group.

Claim 22. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 21, wherein Ar^2 represents a phenyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups from the Substituent group γ, or a monocyclic heteroaryl group which is unsubstituted or substituted with 1 to 5 of the same or different groups from the Substituent group γ,

E represents a formula $-S(O)_{n1}-$ group, wherein n1 is an integer from 0 to 2,

R^4 represents a C_1-C_4 alkyl group,

R^5 represents a hydrogen atom or a C_1-C_4 alkyl group,

G represents a group of a formula (Ga')

$$—(CO)_{p'}—(R^{6'}C=CR^{7'})_{q'}-(C\equiv C)_{r'}—(R^{8'}C=CR^{9'})_{s'}— \quad (Ga')$$

wherein $R^{6'}$, $R^{7'}$, $R^{8'}$ and $R^{9'}$ independently represent a hydrogen atom or a C_1-C_6 alkyl group which is unsubstituted or substituted with 1 to 5 of the same or different halogen atoms,

p' is an integer 0 or 1,and

q', r' and s' independently are an integer from 0 to 2.

Claim 23. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 22, wherein X represents a group of a formula (IV)



(IV)

Claim 24. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 21, wherein

E represents a methylene group,

A^1 represents a group selected from the group consisting of



(B1) (B2) (B3)

G represents a group of a formula (Ga")



(Ga")

wherein, q" is an integer from 0 to 3, and r" and s" independently are an integer from 0 to 2, provided that total of q", r" and s" is 3 or less.

Claim 25. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 24, wherein X represents a group of a formula (V)



(V)

Claim 26. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 21, wherein

Ar^2 represents a naphthyl group which is unsubstituted or substituted with 1 to 5 of the same or different groups selected

from the group consisting of the Substituent group γ, and a fused bicyclic heteroaryl group which is unsubtituted or substituted with 1 to 5 of the same or different groups from Substituent group γ,

E represents a formula $-S(O)_{n1}-$ group, wherein n1 is an integer from 0 to 2,

R^4 represents a C_1-C_6 alkyl group,

R^5 represents a hydrogen atom,

G represents a group of a formula (Ga')

$$—(CO)_{p'}—(R^{6'}C=CR^{7'})_{q'}-(C\equiv C)_{r'}—(R^{8'}C=CR^{9'})_{s'}— \quad (Ga')$$

wherein $R^{6'}$, $R^{7'}$, $R^{8'}$ and $R^{9'}$ independently represent a hydrogen atom or a C_1-C_6 alkyl group which is unsubtituted or substituted with 1 to 5 of the same or different halogen atoms,

p' is an integer 0 or 1, and

q', r' and s' independently are an integer from 0 to 2.

Claim 27. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 21, wherein

Ar^2 represents a phenyl group which may is unsubtituted or substituted with 1 to 5 of the same or different groups selected from the group consisting of the Substituent group γ, and a naphthyl group which is unsubtituted or substituted with 1 to 5 of the same or different groups from the Substituent group γ,

E represents a methylene group or a sulfur atom,

R^5 represents a hydrogen atom, and

G represents a group of a formula (Gb)

$$-\Phi\text{-}CO\text{-}NR^{\Psi}\text{—}T\text{—} \quad (Gb)$$

wherein ϕ represents a phenylene group which is unsubtituted or substituted with 1 or 2 of the same or different groups selected from the group consisting of a fluorine atom and a chlorine atom, or a naphthylene group which is unsubtituted or substituted with 1 or 2 of the same or different groups selected from the group consisting of a fluorine atom and a chlorine atom,

R^{Ψ} represents a hydrogen atom or a C_1-C_6 alkyl group, and

T represents a single bond or a straight or branched chain C_1-C_8 alkylene group.

Claim 28. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (VI)



(VI)

Claim 29. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (VII)



(VII)

Claim 30. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (VIII)



(VIII)

Claim 31. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (IX)



(IX)

Claim 32. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (X)



(X)

Claim 33. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (XI)



(XI)

Claim 34. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (XII)



(XII)

Claim 35. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein X represents a group of a formula (XIII)



(XIII)

Claim 36. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein the compound is dihydrogen 4-cyano-2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]benzyl phosphate.

Claim 37. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 1,

wherein the compound is (1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 5-cyano-2-(hydroxymethyl)benzoate.

Claim 38. (original) The triazole compound or a pharmaceutically acceptable salt according to thereof according to claim 23, wherein

L is



Claim 39. (original) The triazole compound or a pharmaceutically acceptable salt thereof according to claim 23, wherein R is a $-P(=O)(OH)_2$ group.

Claim 40. (original) The triazole compound or a pharmaceutically acceptable salt thereof according to claim 38, wherein R is a $-P(=O)(OH)_2$ group.

Claim 41. (original) The triazole compound or a pharmaceutically acceptable salt thereof according to claim 23, wherein R is a hydrogen atom.

Claim 42. (original) The triazole compound or a pharmaceutically acceptable salt thereof according to claim 38, wherein R is a hydrogen atom.

Claim 43. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 38, wherein R represents a C_1-C_6 alkanoyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the substituent group ß.

Claim 44. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 23, wherein R represents a C_1-C_6 alkanoyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the substituent group ß.

Claim 45. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 22, wherein L is an (o-phenylene)-CH_2- group which is substituted with one group from the Substituent group a.

Claim 46. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 45, wherein R represents a hydrogen atom.

Claim 47. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 45, wherein R represents a C_1-C_6 alkanoyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the substituent group ß.

Claim 48. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 45,

wherein R represents a $-P(=O)(OH)_2$ group.

Claim 49. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 21, wherein L represents an unsubstituted -(o-phenylene)-CH_2- group which is substituted with one group from the substituent group a.

Claim 50. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 49, wherein R represents a hydrogen atom.

Claim 51. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 49, wherein R represents a C_1-C_6 alkanoyl group which is unsubstituted or substituted with 1 to 3 of the same or different groups from the substituent group ß.

Claim 52. (original) The triazole compound or a pharmacologically acceptable salt thereof according to claim 49, wherein R represents a $-P(=O)(OH)_2$ group.

Claim 53. (original) A triazole compound of a formula (I) or a pharmacologically acceptable salt thereof:



(I)

wherein

X represents a group of formula (II),



(II)

wherein,

Ar represents a C_6-C_{10} aryl group which is unsubstituted or substituted with one or more groups selected from the group consisting of a halogen atom and a halogenated C_1-C_6 alkyl group, and

R^1 represents an organic residue group,

provided that a compound of a formula X-OH has antifungal activity,

L represents a C_3-C_4 alkylene group which is unsubstituted or substituted with 1 to 3 groups selected from the group consisting of a Substituent group α; an -O-(C_2-C_3 alkylene) group which is unsubstituted or substituted with 1 to 3 groups from a Substituent group α; an (adjacently substituted C_6-C_{10} aryl)CH_2- group which is unsubstituted or substituted with 1 to 3 groups from the Substituent group α; and an -(adjacently substituted C_3-C_7 cycloalkyl)CH_2- group which is unsubstituted or substituted with 1 to 3 group from the Substituent group α;

R represents a hydrogen atom, a C_1-C_6 alkanoyl group, a C_1-C_6 alkanoyl group which is substituted with 1 to 3 groups from a Substituent group β, and a $-P(=O)(OH)_2$ group

Substituent group α represents a group selected from the group consisting of a C_1-C_6 alkyl group; a C_1-C_6 alkoxy group; a halogen atom; a cyano group; a hydroxy group; an $-NR^2R^3$ group, wherein, R^2 and R^3 each independently represent a hydrogen atom

or a C_1-C_6 alkyl group; a -(C_1-C_6 alkyl)NR^2R^3 group, wherein, R^2 and R^3 have the same meanings as defined above; a carboxyl group; an $-O-P(=O)(OH)_2$ group and a -(C_1-C_6 alkyl)$O-P(=O)(OH)_2$ group;

Substituent group β represents a group selected from the group consisting of a hydroxyl group, an amino group, a carboxyl group, a $-O-P(=O)(OH)_2$ group and an $-SO_3H$ group.

Claim 54. (original) A composition for treating or preventing a fungal infection comprising a pharmaceutically effective amount of the triazole compound or a pharmacologically acceptable salt thereof according to any one of claims 1 to 53 in combination with a pharmaceutically acceptable carrier.

Claim 55. (original) A method for treating or preventing a fungal infection in a warm-blooded animal comprising administering to the warm-blooded animal an effective antifungal amount of the triazole compound or pharmaceutically acceptable salt thereof according to claim 1.

Claim 56. (original) A method for treating or preventing a fungal infection in a human comprising administering to the human an effective antifungal amount of the triazole compound or pharmaceutically acceptable salt according to any one of claims 1 to 53.

Claim 57. (original) A method according to claim 56, wherein the method is for treating a fungal infection; the administering is by injection; and the fungal infection is caused by a fungus of a genus selected from the group consisting of Candida, Aspergillus,

Cryptococcus, Mucor, Histoplasma, Blastomyces, Coccidioides, Paracoccidioides, Trichophyton, Epidermophyton, Microsporum, Malassezia, Pseudallescheria, Sporothrix, Rhinosporidium, Fonsecaea, Wangiella, Phialophora, Exophiala, Cladosporium, Alternaria, Aureobasidium, Chaetomium, Curvularia, Drechslera, Mycocentrospora, Phoma, Hendersonula, Scytalidium, Corynespora, Leptosphaeria, Madurella, Neotestudina, Sedosporium, Pyrenochaeta, Geotrichum, Trichosporon, Chrysosporium, Coprinus, Schizophyllum, Pneumocystis, Conidiobolus, Basidiobolus, Paecilomyces, Penicilliun, Acremonium, Fusarium, Scopulariopsis, Saccharomyces, Cephalosporium, Loboa, Rhizopus, Rhizomucor and Absidia.

Claim 58. (original) The method according to claim 57, wherein the injection is intravenous.

Claim 59. (currently amended) The triazole compound according to claim 1, wherein the compound is selected from the group consisting of
dihydrogen 4-**[[[]]** [(1R,2R)-2-**[[[]]** **[[**trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl}propoxy}- 4-oxobutyl phosphate,
dihydrogen 4-**[[[]]** [(1R,2R)-2- **[[[]]** **[[**trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl}propoxy]-2,2-dimethyl-4-oxobutyl phosphate,
dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-

2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl}propoxy]carbonyl]benzyl phosphate,
dihydrogen 4-cyano-2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2 ,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]benzyl phosphate,
dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-4-fluorobenzyl phosphate,
dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-5-fluorobenzyl phosphate,
dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-6-fluorobenzyl phosphate,
dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-6-methylbenzyl phosphate,
dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-6-methoxybenzyl phosphate,

dihydrogen [8-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-1-naphthyl] methyl phosphate,
dihydrogen 6-chloro-2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]benzyl phosphate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 4-[2-(4-methyl-1-piperazinyl)acetoxy]butyrate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 4-[[4-(4-methyl-1-piperazinyl)-4-oxobutyryl]oxy]butyrate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[2-(N-methylamino)acetoxy]methyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[2-(N,N-dimethylamino)acetoxy]methyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[2-(4-methyl-1-piperazinyl)acetoxy]methyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-

1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1, 2,4-triazol-1-yl)methyl]propyl 2-[[3-N-methylamino) propanoyl]oxymethyl]benzoate,

(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1, 3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H -1,2,4-triazol-1- yl)methyl]propyl 2-[[3-(N,N-dimethylamino) propionyl]oxymethyl]benzoate,

(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[3-(4-methyl-1-piperazinyl)propionyl]oxymethyl]benzoate,

(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[4-(4-methyl-1-piperazinyl)-4-oxobutyryl]oxymethyl]benzoate,

(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-[[4-(N-methylamino) butyryl]oxymethyl] benzoate,

(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 2-
-[[4-(N,N-dimethylamino)butyryl]oxymethyl] benzoate,

(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl] propyl 5-cyano-2-[[2-(N-methylamino) acetoxy]methyl]benzoate,

(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-

1,2,4-triazol-1-yl)methyl]propyl 5-cyano-2-
[[2-(N,N-dimethylamino)acetoxy]methyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-
fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-
(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propyl
5-cyano-2-[[2-(4-methyl-1-piperazinyl)acetoxy]methyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-
1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-
1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 5-cyano-2-
[[3-(N-methylamino)propanoyl]oxymethyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-
fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-
(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl] propyl
5-cyano-2-[[3-(N,N-dimethylamino)propanoyl]oxymethyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-
1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-
1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 5-cyano-2-[[3-(4-methyl-
1-piperazinyl)propanoyl]oxymethyl]benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-
1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-
[(1H-1,2,4-triazol-1-yl)methyl]propyl 5-cyano-2-
[[4-(4-methyl-1-piperazinyl)-4-oxobutyryl]oxymethyl] benzoate,
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-
1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-
1-[(1H-1,2,4-triazol-1-yl)methyl]propyl 5-cyano-2-
[[4-(N-methylamino)butyryl]oxymethyl]benzoate, and
(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-
1,3-butadienyl]-1,3-dioxan-5-yl] thio]-1-(2,4-difluorophenyl)-
1-[(1H-1,2,4-triazol-1-yl)methyl]propyl

5-cyano-2-[[4-(N,N-dimethylamino)butyryl]oxymethyl]benzoate, or a pharmacologically acceptable salt thereof.

Claim 60. (previously presented) The triazole compound according to claim 1, wherein the compound is dihydrogen 4-cyano-2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl) methyl]propoxy]carbonyl]benzyl phosphate or a pharmacologically acceptable salt thereof.

Claim 61. (previously presented) The triazole compound according to claim 1, wherein the compound is dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl) methyl]propoxy]carbonyl]benzyl phosphate or a pharmacologically acceptable salt thereof.

Claim 62. (previously presented) The triazole compound according to claim 1, wherein the compound is dihydrogen 2-([[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-4-fluorobenzyl phosphate or a pharmacologically acceptable salt thereof.

Claim 63. (previously presented) The triazole compound according to claim 1, wherein the compound is dihydrogen 2-[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-

1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]-5-fluorobenzyl phosphate or a pharmacologically acceptable salt thereof.